Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 04/12/24
Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a BetZacks Investment Research • 04/11/24
Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsInvestors Business Daily • 04/11/24
After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX)Zacks Investment Research • 04/08/24
Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 03/28/24
Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to TradeZacks Investment Research • 03/22/24
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)Benzinga • 03/20/24
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsBusiness Wire • 03/08/24
Recent Price Trend in Janux Therapeutics, Inc. (JANX) is Your Friend, Here's WhyZacks Investment Research • 03/01/24
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 02/29/24
Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024Seeking Alpha • 02/27/24
Janux Stock Launches 180% On Its 'Significant Opportunity' In Prostate Cancer TreatmentInvestors Business Daily • 02/27/24
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid TumorsBusiness Wire • 02/26/24
Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last?Zacks Investment Research • 02/21/24